Unbiased metabolome screen leads to personalized medicine strategy for amyotrophic lateral sclerosis. Issue 2 (17th March 2022)

• Record Type: Journal Article
• Authors: Boddy, Sarah; Islam, Mahjabin; Moll, Tobias; Kurz, Julian; Burrows, David; McGown, Alexander; Bhargava, Anushka; Julian, Thomas H; Harvey, Calum; Marshall, Jack NG; Hall, Benjamin PC; Allen, Scott P; Kenna, Kevin P; Sanderson, Eleanor; Zhang, Sai; Ramesh, Tennore; Snyder, Michael P; Shaw, Pamela J; McDermott, Christopher; Cooper-Knock, Johnathan
• Is Part Of: Brain communications. Volume 4:Issue 2(2022)
• Publication Date: 2022-03-17
• Subjects: Metabolome -- amyotrophic lateral sclerosis -- Mendelian randomization -- isoleucine -- vitamin B12; 616
• DOI: 10.1093/braincomms/fcac069
• Languages: English
• ISSNs: 2632-1297

Abstract

Abstract: Amyotrophic lateral sclerosis is a rapidly progressive neurodegenerative disease that affects 1/350 individuals in the United Kingdom. The cause of amyotrophic lateral sclerosis is unknown in the majority of cases. Two-sample Mendelian randomization enables causal inference between an exposure, such as the serum concentration of a specific metabolite, and disease risk. We obtained genome-wide association study summary statistics for serum concentrations of 566 metabolites which were population matched with a genome-wide association study of amyotrophic lateral sclerosis. For each metabolite, we performed Mendelian randomization using an inverse variance weighted estimate for significance testing. After stringent Bonferroni multiple testing correction, our unbiased screen revealed three metabolites that were significantly linked to the risk of amyotrophic lateral sclerosis: Estrone-3-sulphate and bradykinin were protective, which is consistent with literature describing a male preponderance of amyotrophic lateral sclerosis and a preventive effect of angiotensin-converting enzyme inhibitors which inhibit the breakdown of bradykinin. Serum isoleucine was positively associated with amyotrophic lateral sclerosis risk. All three metabolites were supported by robust Mendelian randomization measures and sensitivity analyses; estrone-3-sulphate and isoleucine were confirmed in a validation amyotrophic lateral sclerosis genome-wide association study. Estrone-3-sulphate is metabolized to the more active estradiol by the enzyme 17β-hydroxysteroid dehydrogenase 1; further, Mendelian randomization demonstrated a protective effect of estradiol and rare variant analysis showed that missense variants within HSD17B1, the gene encoding 17β-hydroxysteroid dehydrogenase 1, modify risk for amyotrophic lateral sclerosis. Finally, in a zebrafish model of C9ORF72 -amyotrophic lateral sclerosis, we present evidence that estradiol is neuroprotective. Isoleucine is metabolized via methylmalonyl-CoA mutase encoded by the gene MMUT in a reaction that consumes vitamin B12. Multivariable Mendelian randomization revealed that the toxic effect of isoleucine is dependent on the depletion of vitamin B12; consistent with this, rare variants which reduce the function of MMUT are protective against amyotrophic lateral sclerosis. We propose that amyotrophic lateral sclerosis patients and family members with high serum isoleucine levels should be offered supplementation with vitamin B12. Abstract : Boddy et al. report an unbiased screen of the metabolome using Mendelian randomization to identify underlying determinants of risk for amyotrophic lateral sclerosis. Three metabolites are significant after multiple testing correction: oestrone-3-sulphate and bradykinin were protective and isoleucine was harmful. Estrone-3-sulphate and isoleucine were significant in follow-up analyses. Graphical Abstract: Graphical abstract